Literature DB >> 305386

Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease.

R G Long, E Meinhard, R K Skinner, Z Varghese, M R Wills, S Sherlock.   

Abstract

Twenty of 32 patients with either chronic cholestatic or hepatocellular liver disease had bone pain or recent fractures. On bone biopsy five patients had normal bone, 15 had osteomalacia, five had osteoporosis, and seven had a combination of osteomalacia and osteoporosis. In the presence of osteoporosis, osteomalacia was minimal or absent. There was no biochemical, radiological, or histological evidence of excess parathyroid activity. No significant correlations were demonstrated between the plasma and urinary biochemical findings and the presence of either osteoporosis or osteomalacia and bone biopsy was essential for correct diagnosis. There was no statistical relationship between low serum 25-hydroxy vitamin D values and the presence of osteomalacia. Bone disease was not prevented by regular intramuscular vitamin D2, although biochemical changes were improved. Drugs such as corticosteroids and cholestyramine may be important aetiological factors in hepatic osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305386      PMCID: PMC1411805          DOI: 10.1136/gut.19.2.85

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Analysis of heat inactivation curves of alkaline phosphatase isoenzymes in serum.

Authors:  L G Whitby; D W Moss
Journal:  Clin Chim Acta       Date:  1975-03-24       Impact factor: 3.786

2.  Malabsorption and bone disease in prolonged obstructive jaundice.

Authors:  M ATKINSON; B E NORDIN; S SHERLOCK
Journal:  Q J Med       Date:  1956-07

3.  Serum parathyroid hormone concentration in chronic renal failure patients on maintenance haemodialysis.

Authors:  M R Wills; A Fairney; Z Varghese; G L Tatler; R A Baillod; J F Moorhead
Journal:  Clin Chim Acta       Date:  1974-11-20       Impact factor: 3.786

4.  Silver staining of bone prior to decalcification for quantitative determination of osteoid in sections.

Authors:  E J Tripp; E H MacKay
Journal:  Stain Technol       Date:  1972-05

Review 5.  Vitamins and liver injury.

Authors:  C M Leevy; A Thompson; H Baker
Journal:  Am J Clin Nutr       Date:  1970-04       Impact factor: 7.045

6.  Ascorbic acid deficiency in liver disease.

Authors:  A D Beattie; S Sherlock
Journal:  Gut       Date:  1976-08       Impact factor: 23.059

7.  Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis.

Authors:  J E Compston; R P Thompson
Journal:  Lancet       Date:  1977-04-02       Impact factor: 79.321

8.  Serum-25-hydroxy-vitamin-D in untreated parenchymal and cholestatic liver disease.

Authors:  R G Long; R K Skinner; M R Wills; S Sherlock
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

9.  25-Hydroxylation of vitamin D in primary biliary cirrhosis.

Authors:  R K Skinner; S Sherlock; R G Long; M R Wilis
Journal:  Lancet       Date:  1977-04-02       Impact factor: 79.321

10.  Comparison of vitamin D and 25-hydroxy-vitamin-D in the therapy of primary biliary cirrhosis.

Authors:  J B Wagonfeld; B A Nemchausky; M Bolt; J V Horst; J L Boyer; I H Rosenberg
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321

View more
  27 in total

1.  Osteoporosis and skeletal fractures in chronic liver disease.

Authors:  T Diamond; D Stiel; M Lunzer; M Wilkinson; J Roche; S Posen
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

2.  Perspective in liver disease: An Irish experience.

Authors:  M J Whelton
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

3.  Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.

Authors: 
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

4.  Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels.

Authors:  D D Bikle; B P Halloran; E Gee; E Ryzen; J G Haddad
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

Review 5.  Corticosteroids in liver disease: possible mechanisms of action, pharmacology, and rational use.

Authors:  A R Tanner; L W Powell
Journal:  Gut       Date:  1979-12       Impact factor: 23.059

Review 6.  Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.

Authors:  J E Compston
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

7.  Amount and composition of bone minerals in chronic liver disease.

Authors:  J A Kalef-Ezra; M H Merkouropoulos; A Challa; J Hatzikonstantinou; A H Karantanas; E V Tsianos
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

8.  Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.

Authors:  J E Compston; L W Horton; R P Thompson
Journal:  Gut       Date:  1979-02       Impact factor: 23.059

9.  Vitamin D deficiency, osteomalacia, and primary biliary cirrhosis. Response to orally administered vitamin D3.

Authors:  M Davies; E B Mawer; H J Klass; G A Lumb; J L Berry; T W Warnes
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

Review 10.  Glucocorticosteroids for primary sclerosing cholangitis.

Authors:  Vanja Giljaca; Goran Poropat; Davor Stimac; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.